Needham raised the firm’s price target on Glaukos (GKOS) to $176 from $149 and keeps a Buy rating on the shares after its Q4 results. The ...

Glaukos reported Q4 sales of $105.5 million, surpassing estimates, while EPS missed. Analysts see strong growth potential as ...

Glaukos' fourth-quarter results showcase a strong uptick in revenues. However, continued operating loss and rising OpEx ...

Wells Fargo raised the firm’s price target on Glaukos (GKOS) to $160 from $153 and keeps an Overweight rating on the shares. The firm notes ...

Glaukos Corp (GKOS) reports robust sales growth and outlines strategic initiatives for 2025, while navigating currency and ...

Glaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial results and a robust product ...

Rhumbline Advisers lifted its holdings in Glaukos Co. (NYSE:GKOS – Free Report) by 0.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The ...

Fintel reports that on February 19, 2025, Mizuho upgraded their outlook for Glaukos (NYSE:GKOS) from Neutral to Outperform.

Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ETCompany ParticipantsChris Lewis - Vice President, ...

The results surpassed Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss of 43 cents per share. The glaucoma treatments developer ...

State of New Jersey Common Pension Fund D grew its position in Glaukos Co. (NYSE:GKOS – Free Report) by 2.4% in the fourth quarter, HoldingsChannel.com reports. The firm owned 19,883 shares of the ...